Search clinical trials for: BioChaperone insulin lispro 0.2U/Kg

Total 397 results

Adocia

Completed

A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes

Diabetes Mellitus Type 1

Germany
Adocia
Eli Lilly and Company

Completed

An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects

Healthy

Germany
Adocia

Completed

A Clinical Trial Investigating the Intra-subject Variability of Pharmacokinetics and Glucodynamics of BioChaperone Insulin Lispro U-100 Product and U-200 Product in Healthy Volunteers

Healthy

Germany
Adocia
Eli Lilly and Company

Completed

A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants

Healthy Participants

Singapore
Adocia
Eli Lilly and Company

Completed

To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Germany
Adocia

Completed

Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal

Diabetes Mellitus Type 1

Germany
Adocia
Eli Lilly and Company

Completed

A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®

Type 1 Diabetes Mellitus

Germany
Adocia
Eli Lilly and Company

Completed

A Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Adocia

Completed

A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes

Diabetes Mellitus Type 1

Germany
Adocia

Completed

A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Germany
Adocia

Completed

A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump

Type1 Diabetes Mellitus

Germany
Adocia

Completed

A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes

Germany
Adocia

Completed

A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM

Type 1 Diabetes Mellitus

Germany
Adocia

Completed

A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes

Diabetes Mellitus Type 1

Germany
Wockhardt

Withdrawn

Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Lispro (Listro™) With Humalog® in Healthy Subjects

Bioequivalence in Healthy Subjects

United States
Adocia

Completed

A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Adocia

Completed

Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Germany
Adocia

Completed

A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Germany
Adocia

Completed

A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Germany
Eli Lilly and Company

Completed

A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Taiwan, China, Korea, Republic of
Michael Tsoukas
Adocia

Recruiting

Safety and Efficacy of BC LisPram

Type1 Diabetes Mellitus

Canada
Eli Lilly and Company

Completed

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) (IOOV)

Diabetes Mellitus, Type 2

United States, Canada, India, Puerto Rico, Australia, Spain, Netherlands, Hungary, Brazil, Greece, Romania, Argentina
Eli Lilly and Company

Completed

Bioequivalence of Two Lispro Formulations

Healthy Volunteers

Singapore
Diasome Pharmaceuticals
Integrium

Completed

Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1) (ISLE-1)

Type 1 Diabetes Mellitus

United States
Inreda Diabetic B.V.

Completed

Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes (FAST 1)

Type 1 Diabetes

Netherlands
Eli Lilly and Company

Completed

Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies

Diabetes Mellitus, Type 2

Turkey, Argentina, Korea, Republic of, Brazil, China, Egypt, India, Spain
Universidad de Guanajuato

Completed

Insulin Schemes for Type 2 Diabetes Control

Type 2 Diabetes Mellitus

Mexico
Diasome Pharmaceuticals
Integrium

Completed

Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control

Diabetes Mellitus, Type 1

United States
Sanofi

Completed

A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes

Type 1 Diabetes

Germany
Eli Lilly and Company

Completed

Comparison of Insulin Mix25 Versus Mix50 (CLASSIFY)

Type 2 Diabetes Mellitus

Japan, Korea, Republic of, China, Turkey
Dance Biopharm Inc.
WCCT Global

Terminated

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

Safety and Tolerability

United States
Eli Lilly and Company

Completed

A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes (PRONTO-Pump)

Diabetes Type 1

United States, Spain
Eli Lilly and Company

Completed

Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019) (S019)

Diabetes Mellitus, Type 2

Croatia, Poland, Romania, South Africa, Turkey
Eli Lilly and Company

Completed

A Study for Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Brazil, Canada, Mexico, India, Australia, China, Korea, Republic of
Geropharm

Completed

A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mix 25 to Humalog® Mix 25 in Healthy Subjects

Clamp Study

Russian Federation
Biodel

Completed

Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes

Diabetes Mellitus Type 1

United States
Diasome Pharmaceuticals

Completed

Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec

Diabetes Mellitus, Type 1

United States
Eli Lilly and Company

Completed

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy (PRONTO-Pump-2)

Type 1 Diabetes Mellitus

Spain, United States, France, Israel, Australia, Germany, Italy, Puerto Rico, Austria, Hungary, Canada
University of Cambridge

Completed

Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions (AP@Home04_Phase 4)

Type 1 Diabetes

United Kingdom
Chongqing Medical University

Completed

Pharmacokinetic and Pharmacodynamic Profile of Insulin Lispro Using Needle-Free Jet Injection Technology

Healthy

China
Eli Lilly and Company

Completed

A Study of a New LY900014 Formulation in Healthy Participants

Healthy

Singapore
Eli Lilly and Company

Completed

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

Diabetes Mellitus, Type 1

France, Germany, Hungary
Biodel

Completed

Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes

Type 1 Diabetes
Hompesch, Marcus, M.D.
Profil Institute for Clinical Research, Inc.

Unknown

PK/PD Study of Intranasal Insulin in Type I Diabetes

Type 1 Diabetes

United States
Third Affiliated Hospital, Sun Yat-Sen University
Guangdong Provincial Department of Science and Technology

Unknown

Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes (COGFOST)

Diabetes Mellitus, Type 2

China
Loyola University
Sanofi

Completed

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

Renal Insufficiency | Type 2 Diabetes

United States
Diasome Pharmaceuticals
Integrium

Completed

21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus

Type1 Diabetes Mellitus

United States
Profil Institut für Stoffwechselforschung GmbH

Completed

A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1

Diabetes Mellitus

Germany
Graydon Meneilly

Suspended

Dynamics of Insulin Absorption in Subclinical Lipohypertrophy Using the Euglycemic Clamp Technique

Diabetes Mellitus | Lipohypertrophy

Canada
Medical University of Graz
European Commission

Completed

Absorption of Insulin Following Subcutaneous Bolus Administration With Different Bolus Durations

Type 1 Diabetes

Austria

3

Subscribe